Chimeric fibroblast growth factors
US5302702A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 26, 1993 |
| Grant date | Apr 12, 1994 |
| Priority date | — |
| Expiry date | Feb 26, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/00
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to novel chimeric fibroblast growth factors (FGF) wherein the alanine at amino acid 3 and serine 5 of native human recombinant basic fibroblast growth factor are replaced with glutamic acid. The N-terminus sequence of the present chimeric FGFs identify homology with that of human acidic fibroblast growth factor. The mitogenic properties of the native human recombinant basic FGF are exhibited by the present chimeric FGFs, and they are efficiently expressed in E. coli at significantly greater yields that previously reported. Novel variants of this new glu.sup.3,5 basic fibroblast growth factor, such as those in which cysteine 78 and cysteine 96 are replaced, e.g., with serine or other amino acids, to produce stabilized versions of the glu.sup.3,5 basic FGF and eliminate disulfide scrambled forms, are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.